Ligase Enzyme Market - Global Forecast to 2030
商品番号 : SMB-87853
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年9月 |
| ページ数 | 311 |
| 図表数 | 471 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
リガーゼ酵素市場 – タイプ（DNA、RNA）、ソース（ウイルス、細菌、真核生物）、グレード（RUO、GMP、診断）、分子生物学ワークフロー（クローニング、シーケンシング、合成生物学）、用途（研究、診断、治療） – 2030年の世界予測
リガーゼ酵素市場は、2025年の2億6,000万米ドルから2030年には3億6,000万米ドルに達し、予測期間中は年平均成長率（CAGR）6.8%で成長すると予測されています。リガーゼ酵素市場の成長は、ゲノミクスと次世代シーケンシング（NGS）の導入拡大、分子診断と個別化医療の拡大、そして合成生物学の利用増加に牽引されています。リガーゼは、アダプターライゲーションとライブラリー構築を可能にすることでNGSワークフローにおいて中心的な役割を果たしており、大規模なゲノミクスプロジェクトや精密医療の取り組みにおいて不可欠な存在となっています。分子診断と精密医療におけるリガーゼの応用拡大も、市場の成長を加速させると予想されています。
この調査レポートでは、リガーゼ酵素市場をタイプ別（DNA、RNA、その他のリガーゼ）、ソース別（ウイルス、細菌、古細菌、真核生物）、グレード別（RUO、GMP、診断）、分子生物学ワークフロー別（クローニングと突然変異誘発、合成生物学、シーケンシング、核酸増幅）、用途別（研究、診断、治療薬の開発と製造、その他の用途）、エンドユーザー別（学術機関と研究機関、製薬会社とバイオテクノロジー会社、病院と診断研究所、医療機器会社）、地域別（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。
本レポートは、リガーゼ酵素市場の成長に影響を与える重要な要因（成長促進要因、トレンド、課題、機会など）に関する詳細な情報を提供しています。主要企業を徹底的に分析し、事業概要、製品、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。さらに、本レポートでは、リガーゼ酵素市場における新製品の発売や買収といった最近の動向も網羅しています。
本レポートは、リガーゼ酵素市場とそのサブセグメントの収益数値に最も近い近似値を提供することで、市場リーダー企業や新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。
The ligase enzymes market is expected to reach USD 0.36 billion in 2030 from USD 0.26 billion in 2025, at a CAGR of 6.8% during the forecast period. The growth of the ligase enzymes market is driven by the rising adoption of genomics and next-generation sequencing (NGS), the expansion of molecular diagnostics and personalized medicine, and the increasing use of synthetic biology. Ligases play a central role in NGS workflows by enabling adapter ligation & library construction, making them indispensable in large-scale genomics projects and precision medicine initiatives. Its growing application in molecular diagnostics and precision medicine is also expected to fuel the market growth.
By grade, the GMP-grade ligase enzymes segment is projected to register the highest CAGR during the forecast period.
By grade, the ligase enzymes market is segmented into Research Use Only (RUO), GMP-grade, and diagnostic-grade ligase enzymes. The GMP-grade ligase enzymes segment is expected to grow at the highest CAGR during the forecast period. The growth is supported by the rising demand for GMP-grade ligase enzymes in therapeutic manufacturing, gene therapy, and clinical applications where compliance with stringent quality and safety standards is essential. The increasing investments in cell & gene therapies, biopharmaceutical production, and diagnostic assay development are also expected to fuel the market growth.
By source, the viral sources segment accounted for the largest share of the market in 2024.
Based on the source, the ligase enzymes market is segmented into viral, bacterial, archaeal, and eukaryotic sources. In 2024, the viral ligases segment accounted for the largest market share owing to its high adoption in applications such as molecular biology workflows, particularly in cloning, DNA repair studies, and next-generation sequencing (NGS) library preparation. Viral ligases, such as T4 DNA ligase, are considered industry standards because of their high efficiency in catalyzing the joining of DNA fragments, making them indispensable in research & industrial biotechnology.
By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period.
By region, the market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period owing to the increasing investments in genomics research, expansion in biotechnology & pharmaceutical industries, and the rising focus on precision medicine. China, Japan, South Korea, and India are significantly scaling up their R&D capabilities through government funding, public–private partnerships, and international collaborations, creating strong demand for molecular biology tools, including ligase enzymes. The growing adoption of next-generation sequencing (NGS), synthetic biology, and molecular diagnostics for cancer, infectious diseases, and rare genetic disorders further supports market expansion.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
- By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
- By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, and the Rest of the World- 15%
Promega Corporation (US), New England Biolabs (UK), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), and Takara Bio Inc. (Japan) are some of the key players in the ligase enzymes market.
The study includes an in-depth competitive analysis of these key players in the ligase enzymes market and their company profiles, recent developments, and key market strategies.
Research Coverage:
This research report categorizes the ligase enzymes market by type (DNA, RNA, other ligases), by source (viral, bacterial, archaeal, eukaryotic), by grade (RUO, GMP, diagnostic), by molecular biology workflow (cloning & mutagenesis, synthetic biology, sequencing, nucleic acid amplification), by application (research, diagnostic, therapeutic development & manufacturing, other applications), by end user (academic & research institutes, pharmaceutical and biotechnology companies, hospital & diagnostic laboratories, medical device companies), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report provides in-depth information on significant factors influencing the growth of the ligase enzymes market, including drivers, trends, challenges, and opportunities. A thorough analysis of leading industry players has been undertaken to provide insights into their business profiles, products, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the ligase enzyme market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the ligase enzyme market and its subsegments. It will also help stakeholders better understand the competitive landscape & gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (rising genomics & NGS activities, growth of molecular diagnostics & personalized medicine, and increasing use in synthetic biology), restraints (dependency on research funding), opportunities (development of thermostable/performance-engineered ligases, development of lyophilized/shelf-stable ligases for point-of-care testing and low-resource markets), and challenges (batch-to-batch variability & quality control, growing adoption of ligase independent cloning) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the ligase enzyme market
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ligase enzyme market
- Competitive Assessment: In-depth assessment of market share, growth strategies of leading players like New England Biolabs (UK), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), and Promega Corporation (US), among others, in the ligase enzymes market.
Table of Contents
1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 31
1.3.2 INCLUSIONS & EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 33
1.3.4 CURRENCY CONSIDERED 33
1.4 STAKEHOLDERS 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 35
2.1.2 PRIMARY DATA 35
2.2 MARKET ESTIMATION METHODOLOGY 37
2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024 37
2.2.2 SEGMENTAL MARKET ASSESSMENT 40
2.3 MARKET GROWTH RATE PROJECTIONS 42
2.4 DATA TRIANGULATION 44
2.5 RESEARCH ASSUMPTIONS 45
2.6 RESEARCH LIMITATIONS 46
2.7 RISK ASSESSMENT 46
3 EXECUTIVE SUMMARY 47
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS 47
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN LIGASE ENZYMES MARKET 52
3.3 DISRUPTIVE TRENDS SHAPING LIGASE ENZYMES MARKET 53
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 53
4 PREMIUM INSIGHTS 54
4.1 GLOBAL LIGASE ENZYMES MARKET SNAPSHOT 54
4.2 NORTH AMERICA: LIGASE ENZYMES MARKET, BY TYPE AND COUNTRY (2024) 55
4.3 LIGASE ENZYMES MARKET, BY TYPE (2024) 55
4.4 LIGASE ENZYMES MARKET, BY END USER (2024) 56
4.5 LIGASE ENZYMES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
4.6 UNMET NEEDS & WHITE SPACES 57
4.7 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 57
4.7.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 57
4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 58
4.9 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Rising genomics & NGS activity 61
5.2.1.2 Growth of molecular diagnostics & personalized medicine 62
5.2.1.3 Growing use in synthetic biology 62
5.2.2 RESTRAINTS 63
5.2.2.1 Dependence on research funding 63
5.2.3 OPPORTUNITIES 63
5.2.3.1 Development of thermostable/performance-engineered ligases 63
5.2.3.2 Development of lyophilized/shelf-stable ligases for point-of-
care testing (POCT) and low-resource markets 64
5.2.4 CHALLENGES 64
5.2.4.1 Batch-to-batch variability & quality control 64
5.2.4.2 Growth in adoption of sequence and ligase-independent
cloning (SLIC) 65
6 INDUSTRY TRENDS 66
6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 66
6.1.1 SHIFT TOWARD HIGH-THROUGHPUT & AUTOMATED WORKFLOWS 66
6.1.2 EXPANSION OF LIGASE APPLICATIONS IN RAPID & POINT-OF-CARE TESTING 66
6.2 VALUE CHAIN ANALYSIS 67
6.3 ECOSYSTEM ANALYSIS 69
6.4 TECHNOLOGY ANALYSIS 70
6.4.1 KEY TECHNOLOGIES 70
6.4.1.1 Precision fermentation 70
6.4.1.2 Enzyme engineering & protein design 71
6.4.2 COMPLEMENTARY TECHNOLOGIES 71
6.4.2.1 Chromatography & purification technologies 71
6.4.2.2 Cryopreservation & stabilization technologies 71
6.5 PATENT ANALYSIS 71
6.5.1 METHODOLOGY 71
6.5.2 PATENTS APPLIED & GRANTED, 2014–2024 72
6.6 TRADE ANALYSIS 74
6.6.1 IMPORT DATA (HS CODE 350790) 74
6.6.2 EXPORT DATA (HS CODE 350790) 76
6.7 PORTER’S FIVE FORCES ANALYSIS 77
6.7.1 THREAT OF NEW ENTRANTS 78
6.7.2 THREAT OF SUBSTITUTES 78
6.7.3 BARGAINING POWER OF SUPPLIERS 78
6.7.4 BARGAINING POWER OF BUYERS 78
6.7.5 INTENSITY OF COMPETITIVE RIVALRY 79
6.8 TARIFF & REGULATORY LANDSCAPE 79
6.8.1 TARIFF DATA (HS CODE 350790) 79
6.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
6.8.3 REGULATORY FRAMEWORK 82
6.9 PRICING ANALYSIS 84
6.9.1 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES,
BY KEY PLAYER, 2022–2024 84
6.9.2 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024 85
6.10 KEY CONFERENCES & EVENTS, 2025–2026 86
6.11 KEY STAKEHOLDERS & BUYING CRITERIA 87
6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
6.11.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS 88
6.11.3 BUYING CRITERIA 89
6.12 INVESTMENT & FUNDING SCENARIO 90
6.13 IMPACT OF AI/GENERATIVE AI ON LIGASE ENZYMES MARKET 90
6.13.1 AI USE CASES 91
6.13.2 KEY COMPANIES IMPLEMENTING AI 92
6.13.3 FUTURE OF AI 92
6.14 IMPACT OF 2025 US TARIFFS ON LIGASE ENZYMES MARKET 92
6.14.1 INTRODUCTION 92
6.14.2 KEY TARIFF RATES 93
6.14.3 PRICE IMPACT ANALYSIS 93
6.14.4 IMPACT ON COUNTRY/REGION 93
6.14.4.1 US 93
6.14.4.2 Europe 94
6.14.4.3 Asia Pacific 94
6.14.5 END-USE INDUSTRY IMPACT 95
6.14.5.1 Pharmaceutical & biotechnology companies 95
6.14.5.2 Medical device companies 95
6.14.5.3 Academic & research institutes 95
6.14.5.4 Hospitals & diagnostic laboratories 95
7 LIGASE ENZYMES MARKET, BY TYPE 96
7.1 INTRODUCTION 97
7.2 DNA LIGASES 97
7.2.1 HIGH ADOPTION OF DNA LIGASES TO SUPPORT MARKET GROWTH 97
7.3 RNA LIGASES 100
7.3.1 GROWING ADOPTION OF RNA SEQUENCING AND DEVELOPMENT IN RNA THERAPEUTICS TO DRIVE MARKET GROWTH 100
7.4 OTHER LIGASES 103
8 LIGASE ENZYMES MARKET, BY SOURCE 106
8.1 INTRODUCTION 107
8.2 VIRAL LIGASES 107
8.2.1 WIDE COMMERCIAL USE OF VIRAL LIGASES BY COMPANIES
TO SUPPORT MARKET GROWTH 107
8.3 BACTERIAL LIGASES 110
8.3.1 HIGH SPECIFICITY AND COMPATIBILITY OF BACTERIAL LIGASES WITH CERTAIN APPLICATIONS TO SUPPORT MARKET GROWTH 110
8.4 EUKARYOTIC LIGASES 113
8.4.1 EXPANDING ROLE OF EUKARYOTIC LIGASES IN DNA REPAIR ASSAYS
AND CRISPR-MEDIATED GENOME EDITING TO BOOST MARKET 113
8.5 ARCHAEAL LIGASES 116
8.5.1 RISING DEMAND FOR HIGH-TEMPERATURE LIGATION METHODS
IN PCR CLONING TO FUEL GROWTH 116
9 LIGASE ENZYMES MARKET, BY GRADE 119
9.1 INTRODUCTION 120
9.2 RUO-GRADE LIGASES 120
9.2.1 LOW COST OF RUO-GRADE LIGASE ENZYMES TO SUPPORT MARKET GROWTH 120
9.3 GMP-GRADE LIGASES 123
9.3.1 GROWING PIPELINE FOR DNA AND RNA-BASED THERAPEUTICS
TO SUPPORT MARKET GROWTH 123
9.4 DIAGNOSTIC-GRADE LIGASES 126
9.4.1 CONTINUOUS PRODUCT INNOVATION TO POSITION DIAGNOSTIC-GRADE LIGASES AS HIGH-OPPORTUNITY GROWTH SEGMENT 126
10 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW 129
10.1 INTRODUCTION 130
10.2 CLONING & MUTAGENESIS 130
10.2.1 WIDE ADOPTION OF CLONING TECHNIQUES TO SUPPORT MARKET GROWTH 130
10.3 SYNTHETIC BIOLOGY 133
10.3.1 GROWING EXPANSION OF SYNTHETIC BIOLOGY IN HEALTHCARE TO DRIVE MARKET GROWTH 133
10.4 SEQUENCING 136
10.4.1 INCREASING DEMAND FOR LARGE-SCALE GENOME PROJECTS
TO BOOST MARKET GROWTH 136
10.5 NUCLEIC ACID AMPLIFICATION 139
10.5.1 GROWING DEMAND FOR RAPID, ACCURATE, AND COST-EFFECTIVE MOLECULAR DIAGNOSTICS TO SUPPORT MARKET GROWTH 139
11 LIGASE ENZYMES MARKET, BY APPLICATION 142
11.1 INTRODUCTION 143
11.2 RESEARCH APPLICATIONS 143
11.2.1 GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH 143
11.3 DIAGNOSTIC APPLICATIONS 146
11.3.1 GROWING DEMAND FOR MOLECULAR DIAGNOSTICS AND PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH 146
11.4 THERAPEUTIC DEVELOPMENT & MANUFACTURING 149
11.4.1 GROWING DEMAND FOR GMP-GRADE ENZYMES IN LARGE-SCALE MANUFACTURING TO PROPEL MARKET GROWTH 149
11.5 OTHER APPLICATIONS 152
12 LIGASE ENZYMES MARKET, BY END USER 155
12.1 INTRODUCTION 156
12.2 ACADEMIC & RESEARCH INSTITUTES 156
12.2.1 GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH 156
12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 159
12.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO BOOST
MARKET GROWTH 159
12.4 HOSPITALS & DIAGNOSTIC LABORATORIES 162
12.4.1 GROWING INTEGRATION OF LIGASE-BASED MOLECULAR DIAGNOSTIC
TESTS INTO ROUTINE CARE TO SUPPORT MARKET GROWTH 162
12.5 MEDICAL DEVICE COMPANIES 164
12.5.1 GROWING FOCUS ON RAPID, RELIABLE, AND USER-FRIENDLY DIAGNOSTIC DEVICES TO FUEL GROWTH 164
13 LIGASE ENZYMES MARKET, BY REGION 168
13.1 INTRODUCTION 169
13.2 NORTH AMERICA 169
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 173
13.2.2 US 174
13.2.2.1 Increasing R&D investments and funding to drive market 174
13.2.3 CANADA 176
13.2.3.1 Supportive government policies to propel market growth 176
13.3 EUROPE 179
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 182
13.3.2 GERMANY 183
13.3.2.1 Strong healthcare infrastructure and government-backed genomics initiatives to support market 183
13.3.3 UK 185
13.3.3.1 Growing adoption of genomics and presence of advanced research infrastructure to drive demand 185
13.3.4 FRANCE 188
13.3.4.1 Growing government funding for R&D to propel market 188
13.3.5 ITALY 190
13.3.5.1 Growing research funding to drive market growth 190
13.3.6 SPAIN 193
13.3.6.1 Increasing number of biotechnology companies to drive demand 193
13.3.7 REST OF EUROPE 195
13.4 ASIA PACIFIC 198
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 201
13.4.2 CHINA 202
13.4.2.1 Increasing R&D expenditure to support market growth 202
13.4.3 JAPAN 204
13.4.3.1 Advanced biotechnology industry and strong research base to support market growth 204
13.4.4 INDIA 206
13.4.4.1 Growing government support in evolving biotechnology sector to boost market 206
13.4.5 SOUTH KOREA 209
13.4.5.1 Increasing government support to boost market 209
13.4.6 AUSTRALIA 211
13.4.6.1 Growing biotechnology sector to boost demand 211
13.4.7 REST OF ASIA PACIFIC 213
13.5 LATIN AMERICA 216
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 218
13.5.2 BRAZIL 219
13.5.2.1 Rising focus on biotechnology industry to support market 219
13.5.3 MEXICO 221
13.5.3.1 Government support for biopharmaceutical production to drive market 221
13.5.4 REST OF LATIN AMERICA 224
13.6 MIDDLE EAST 226
13.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST 229
13.6.2 GCC COUNTRIES 229
13.6.2.1 Saudi Arabia 232
13.6.2.1.1 Increasing investments in genomics to drive market 232
13.6.2.2 United Arab Emirates 234
13.6.2.2.1 Advancements in biopharmaceutical sector to drive demand 234
13.6.2.3 Rest of GCC Countries 237
13.6.3 REST OF MIDDLE EAST 239
13.7 AFRICA 241
13.7.1 GROWING FUNDING FOR SUPPORTING RESEARCH INFRASTRUCTURE
TO DRIVE MARKET 241
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 244
14 COMPETITIVE LANDSCAPE 245
14.1 OVERVIEW 245
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2025 245
14.3 REVENUE ANALYSIS, 2020–2024 246
14.4 MARKET SHARE ANALYSIS, 2024 247
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 250
14.5.1 STARS 250
14.5.2 EMERGING LEADERS 250
14.5.3 PERVASIVE PLAYERS 250
14.5.4 PARTICIPANTS 251
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 252
14.5.5.1 Company footprint 252
14.5.5.2 Region footprint 253
14.5.5.3 Type footprint 254
14.5.5.4 Source footprint 254
14.5.5.5 Application footprint 255
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 256
14.6.1 PROGRESSIVE COMPANIES 256
14.6.2 RESPONSIVE COMPANIES 256
14.6.3 DYNAMIC COMPANIES 256
14.6.4 STARTING BLOCKS 256
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 258
14.6.5.1 Detailed list of key startups/SMEs 258
14.6.5.2 Competitive benchmarking of key startups/SMEs 259
14.7 COMPANY VALUATION & FINANCIAL METRICS 260
14.7.1 FINANCIAL METRICS 260
14.7.2 COMPANY VALUATION 260
14.8 BRAND/PRODUCT COMPARISON 261
14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS 261
14.9 COMPETITIVE SCENARIO 261
14.9.1 DEALS 261
15 COMPANY PROFILES 262
15.1 KEY PLAYERS 262
15.1.1 NEW ENGLAND BIOLABS 262
15.1.1.1 Business overview 262
15.1.1.2 Products offered 262
15.1.1.3 MnM view 263
15.1.1.3.1 Key strengths 263
15.1.1.3.2 Strategic choices 263
15.1.1.3.3 Weaknesses & competitive threats 263
15.1.2 THERMO FISHER SCIENTIFIC INC. 264
15.1.2.1 Business overview 264
15.1.2.2 Products offered 265
15.1.2.3 MnM view 266
15.1.2.3.1 Key strengths 266
15.1.2.3.2 Strategic choices 266
15.1.2.3.3 Weaknesses & competitive threats 266
15.1.3 QIAGEN N.V. 267
15.1.3.1 Business overview 267
15.1.3.2 Products offered 268
15.1.3.3 MnM view 269
15.1.3.3.1 Key strengths 269
15.1.3.3.2 Strategic choices 269
15.1.3.3.3 Weaknesses & competitive threats 269
15.1.4 PROMEGA CORPORATION 270
15.1.4.1 Business overview 270
15.1.4.2 Products offered 270
15.1.4.3 MnM view 271
15.1.4.3.1 Key strengths 271
15.1.4.3.2 Strategic choices 271
15.1.4.3.3 Weaknesses & competitive threats 271
15.1.5 TAKARA BIO INC. 272
15.1.5.1 Business overview 272
15.1.5.2 Products offered 273
15.1.5.3 MnM view 274
15.1.5.3.1 Key strengths 274
15.1.5.3.2 Strategic choices 274
15.1.5.3.3 Weaknesses & competitive threats 274
15.1.6 DANAHER CORPORATION 275
15.1.6.1 Business overview 275
15.1.6.2 Products offered 276
15.1.6.3 MnM view 277
15.1.6.3.1 Key strengths 277
15.1.6.3.2 Strategic choices 277
15.1.6.3.3 Weaknesses & competitive threats 277
15.1.7 AGILENT TECHNOLOGIES, INC. 278
15.1.7.1 Business overview 278
15.1.7.2 Products offered 279
15.1.8 F. HOFFMANN-LA ROCHE LTD. 280
15.1.8.1 Business overview 280
15.1.8.2 Products offered 281
15.1.8.3 Recent developments 282
15.1.8.3.1 Deals 282
15.1.9 MERCK KGAA 283
15.1.9.1 Business overview 283
15.1.9.2 Products offered 284
15.1.10 ARCTICZYMES TECHNOLOGIES 285
15.1.10.1 Business overview 285
15.1.10.2 Products offered 286
15.1.11 BIOSYNTH 287
15.1.11.1 Business overview 287
15.1.11.2 Products offered 287
15.1.12 HIMEDIA LABORATORIES 288
15.1.12.1 Business overview 288
15.1.12.2 Products offered 288
15.1.13 LGC BIOSEARCH TECHNOLOGIES 289
15.1.13.1 Business overview 289
15.1.13.2 Products offered 289
15.1.14 INSPIRALIS LIMITED 290
15.1.14.1 Business overview 290
15.1.14.2 Products offered 290
15.1.15 BIONEER CORPORATION 291
15.1.15.1 Business overview 291
15.1.15.2 Products offered 291
15.2 OTHER PLAYERS 292
15.2.1 GENO TECHNOLOGY INC. 292
15.2.2 MBR, INC. 292
15.2.3 ABCLONAL, INC. 293
15.2.4 NZYTECH 294
15.2.5 JENA BIOSCIENCE GMBH 295
15.2.6 CREATIVE ENZYMES. 295
15.2.7 ENZYNOMICS CO., LTD. 296
15.2.8 BIOCAT GMBH 297
15.2.9 GENAXXON BIOSCIENCE 298
15.2.10 MERIDIAN BIOSICENCE 299
15.2.11 CANVAX 300
15.2.12 BIOTECHRABBIT 301
15.2.13 MCLAB 302
16 APPENDIX 303
16.1 DISCUSSION GUIDE 303
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 307
16.3 CUSTOMIZATION OPTIONS 309
16.4 RELATED REPORTS 309
16.5 AUTHOR DETAILS 310
LIST OF TABLES
TABLE 1 LIGASE ENZYMES MARKET: INCLUSIONS & EXCLUSIONS 32
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 43
TABLE 3 LIGASE ENZMES MARKET: RISK ASSESSMENT ANALYSIS 46
TABLE 4 LIGASE ENZYMES MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 57
TABLE 5 LIGASE ENZYMES MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS 58
TABLE 6 LIGASE ENZYMES MARKET: IMPACT ANALYSIS 61
TABLE 7 LIGASE ENZYMES MARKET: RAW MATERIAL VENDORS 70
TABLE 8 PATENTS APPLIED & GRANTED, 2014–2024 72
TABLE 9 INNOVATIONS & PATENT REGISTRATIONS, 2024 73
TABLE 10 IMPORT VALUE OF HS CODE 350790-COMPLIANT PRODUCTS FOR
TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND) 74
TABLE 11 IMPORT VOLUME FOR HS CODE 350790-COMPLIANT PRODUCTS FOR
TOP 20 COUNTRIES, 2020–2024 (TONS) 75
TABLE 12 EXPORT VALUE OF HS CODE 350790-COMPLIANT PRODUCTS FOR
TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND) 76
TABLE 13 EXPORT VOLUME FOR HS CODE 350790-COMPLIANT PRODUCTS
FOR TOP 20 COUNTRIES, 2020–2024 (TONS) 76
TABLE 14 LIGASE ENZYMES MARKET: PORTER’S FIVE FORCES ANALYSIS 78
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS 80
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 19 LIGASE ENZYMES MARKET: REGULATORY GUIDELINES 82
TABLE 20 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES,
BY KEY PLAYER, 2022–2024 84
TABLE 21 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024 (USD) 85
TABLE 22 LIGASE ENZYMES MARKET: KEY CONFERENCES & EVENTS, 2025–2026 86
TABLE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR LIGASE ENZYMES 88
TABLE 24 BUYING CRITERIA FOR LIGASE ENZYMES, BY END USER 89
TABLE 25 KEY COMPANIES IMPLEMENTING AI IN LIGASE ENZYMES MARKET 92
TABLE 26 LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 97
TABLE 27 DNA LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 98
TABLE 28 NORTH AMERICA: DNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 98
TABLE 29 EUROPE: DNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 98
TABLE 30 ASIA PACIFIC: DNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 99
TABLE 31 LATIN AMERICA: DNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 99
TABLE 32 MIDDLE EAST: DNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 99
TABLE 33 GCC COUNTRIES: DNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 100
TABLE 34 RNA LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 101
TABLE 35 NORTH AMERICA: RNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 101
TABLE 36 EUROPE: RNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 101
TABLE 37 ASIA PACIFIC: RNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 102
TABLE 38 LATIN AMERICA: RNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 102
TABLE 39 MIDDLE EAST: RNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 102
TABLE 40 GCC COUNTRIES: RNA LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 103
TABLE 41 OTHER LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 42 NORTH AMERICA: OTHER LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 104
TABLE 43 EUROPE: OTHER LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 104
TABLE 44 ASIA PACIFIC: OTHER LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 104
TABLE 45 LATIN AMERICA: OTHER LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 105
TABLE 46 MIDDLE EAST: OTHER LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 105
TABLE 47 GCC COUNTRIES: OTHER LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 105
TABLE 48 LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 107
TABLE 49 VIRAL LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 108
TABLE 50 NORTH AMERICA: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 51 EUROPE: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 52 ASIA PACIFIC: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 53 LATIN AMERICA: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 54 MIDDLE EAST: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 55 GCC COUNTRIES: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 56 BACTERIAL LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 57 NORTH AMERICA: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 58 EUROPE: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 59 ASIA PACIFIC: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 60 LATIN AMERICA: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 61 MIDDLE EAST: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 62 GCC COUNTRIES: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 63 EUKARYOTIC LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 113
TABLE 64 NORTH AMERICA: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 113
TABLE 65 EUROPE: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 66 ASIA PACIFIC: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 67 LATIN AMERICA: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 115
TABLE 68 MIDDLE EAST: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 115
TABLE 69 GCC COUNTRIES: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 115
TABLE 70 ARCHAEAL LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 71 NORTH AMERICA: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 117
TABLE 72 EUROPE: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 117
TABLE 73 ASIA PACIFIC: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 117
TABLE 74 LATIN AMERICA: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 118
TABLE 75 MIDDLE EAST: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 118
TABLE 76 GCC COUNTRIES: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 118
TABLE 77 LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 120
TABLE 78 RUO-GRADE LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 121
TABLE 79 NORTH AMERICA: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 80 EUROPE: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 81 ASIA PACIFIC: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 82 LATIN AMERICA: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 83 MIDDLE EAST: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 84 GCC COUNTRIES: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 123
TABLE 85 GMP-GRADE LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 123
TABLE 86 NORTH AMERICA: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 124
TABLE 87 EUROPE: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 124
TABLE 88 ASIA PACIFIC: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 124
TABLE 89 LATIN AMERICA: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 90 MIDDLE EAST: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 91 GCC COUNTRIES: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 92 DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY REGION,
2023–2030 (USD MILLION) 126
TABLE 93 NORTH AMERICA: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 94 EUROPE: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 95 ASIA PACIFIC: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 96 LATIN AMERICA: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 97 MIDDLE EAST: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 98 GCC COUNTRIES: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 99 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW,
2023–2030 (USD MILLION) 130
TABLE 100 LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY REGION,
2023–2030 (USD MILLION) 131
TABLE 101 NORTH AMERICA: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS,
BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 102 EUROPE: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS,
BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 103 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS,
BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 104 LATIN AMERICA: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS,
BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 105 MIDDLE EAST: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS,
BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 106 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS,
BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 107 LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY REGION,
2023–2030 (USD MILLION) 133
TABLE 108 NORTH AMERICA: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 109 EUROPE: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 110 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 111 LATIN AMERICA: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 112 MIDDLE EAST: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 113 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 114 LIGASE ENZYMES MARKET FOR SEQUENCING, BY REGION,
2023–2030 (USD MILLION) 136
TABLE 115 NORTH AMERICA: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 116 EUROPE: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY,
2023–2030 (USD MILLION) 137
TABLE 117 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY,
2023–2030 (USD MILLION) 137
TABLE 118 LATIN AMERICA: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 119 MIDDLE EAST: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY,
2023–2030 (USD MILLION) 138
TABLE 120 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 121 LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY REGION,
2023–2030 (USD MILLION) 139
TABLE 122 NORTH AMERICA: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 123 EUROPE: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 124 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 125 LATIN AMERICA: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION,
BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 126 MIDDLE EAST: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION,
BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 127 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 128 LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 143
TABLE 129 LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 144
TABLE 130 NORTH AMERICA: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 131 EUROPE: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 132 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 133 LATIN AMERICA: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 134 MIDDLE EAST: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 135 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 136 LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 147
TABLE 137 NORTH AMERICA: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 138 EUROPE: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 139 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 140 LATIN AMERICA: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 141 MIDDLE EAST: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 142 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 143 LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 150
TABLE 144 NORTH AMERICA: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT
& MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 145 EUROPE: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 146 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT
& MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 147 LATIN AMERICA: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 148 MIDDLE EAST: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT
& MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 149 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT
& MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 150 LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 152
TABLE 151 NORTH AMERICA: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 152 EUROPE: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 153 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 154 LATIN AMERICA: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 155 MIDDLE EAST: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 156 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 157 LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 156
TABLE 158 LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2023–2030 (USD MILLION) 157
TABLE 159 NORTH AMERICA: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 160 EUROPE: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 161 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 162 LATIN AMERICA: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 163 MIDDLE EAST: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 164 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 165 LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 159
TABLE 166 NORTH AMERICA: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 167 EUROPE: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 168 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 169 LATIN AMERICA: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 170 MIDDLE EAST: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 171 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 172 LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES,
BY REGION, 2023–2030 (USD MILLION) 162
TABLE 173 NORTH AMERICA: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 174 EUROPE: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 175 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 176 LATIN AMERICA: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 177 MIDDLE EAST: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 178 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 179 LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES,
BY REGION, 2023–2030 (USD MILLION) 165
TABLE 180 NORTH AMERICA: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 181 EUROPE: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 182 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 183 LATIN AMERICA: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 184 MIDDLE EAST: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 185 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 186 LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 169
TABLE 187 NORTH AMERICA: LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 170
TABLE 188 NORTH AMERICA: LIGASE ENZYMES MARKET, BY TYPE,
2023–2030 (USD MILLION) 171
TABLE 189 NORTH AMERICA: LIGASE ENZYMES MARKET, BY GRADE,
2023–2030 (USD MILLION) 171
TABLE 190 NORTH AMERICA: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 171
TABLE 191 NORTH AMERICA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 172
TABLE 192 NORTH AMERICA: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 172
TABLE 193 NORTH AMERICA: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 172
TABLE 194 NORTH AMERICA: MACROECONOMIC INDICATORS 173
TABLE 195 US: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 174
TABLE 196 US: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 174
TABLE 197 US: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 175
TABLE 198 US: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW,
2023–2030 (USD MILLION) 175
TABLE 199 US: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 175
TABLE 200 US: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 176
TABLE 201 CANADA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 177
TABLE 202 CANADA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 177
TABLE 203 CANADA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 177
TABLE 204 CANADA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 178
TABLE 205 CANADA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 178
TABLE 206 CANADA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 178
TABLE 207 EUROPE: LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 208 EUROPE: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 209 EUROPE: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 180
TABLE 210 EUROPE: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 180
TABLE 211 EUROPE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 181
TABLE 212 EUROPE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 181
TABLE 213 EUROPE: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 181
TABLE 214 EUROPE: MACROECONOMIC INDICATORS 182
TABLE 215 GERMANY: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 183
TABLE 216 GERMANY: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 183
TABLE 217 GERMANY: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 184
TABLE 218 GERMANY: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 184
TABLE 219 GERMANY: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 184
TABLE 220 GERMANY: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 185
TABLE 221 UK: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 186
TABLE 222 UK: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 186
TABLE 223 UK: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 186
TABLE 224 UK: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW,
2023–2030 (USD MILLION) 187
TABLE 225 UK: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 187
TABLE 226 UK: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 187
TABLE 227 FRANCE: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 228 FRANCE: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 189
TABLE 229 FRANCE: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 189
TABLE 230 FRANCE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 189
TABLE 231 FRANCE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 190
TABLE 232 FRANCE: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 190
TABLE 233 ITALY: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 234 ITALY: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 191
TABLE 235 ITALY: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 192
TABLE 236 ITALY: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 192
TABLE 237 ITALY: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 192
TABLE 238 ITALY: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 193
TABLE 239 SPAIN: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 240 SPAIN: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 194
TABLE 241 SPAIN: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 194
TABLE 242 SPAIN: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 194
TABLE 243 SPAIN: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 195
TABLE 244 SPAIN: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 195
TABLE 245 REST OF EUROPE: LIGASE ENZYMES MARKET, BY TYPE,
2023–2030 (USD MILLION) 196
TABLE 246 REST OF EUROPE: LIGASE ENZYMES MARKET, BY GRADE,
2023–2030 (USD MILLION) 196
TABLE 247 REST OF EUROPE: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 196
TABLE 248 REST OF EUROPE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 197
TABLE 249 REST OF EUROPE: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 197
TABLE 250 REST OF EUROPE: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 197
TABLE 251 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 199
TABLE 252 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 199
TABLE 253 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 199
TABLE 254 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 200
TABLE 255 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 200
TABLE 256 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 200
TABLE 257 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 201
TABLE 258 ASIA PACIFIC: MACROECONOMIC INDICATORS 201
TABLE 259 CHINA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 202
TABLE 260 CHINA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 202
TABLE 261 CHINA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 203
TABLE 262 CHINA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW,
2023–2030 (USD MILLION) 203
TABLE 263 CHINA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 203
TABLE 264 CHINA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 204
TABLE 265 JAPAN: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 266 JAPAN: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 205
TABLE 267 JAPAN: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 205
TABLE 268 JAPAN: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 205
TABLE 269 JAPAN: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206
TABLE 270 JAPAN: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 206
TABLE 271 INDIA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 207
TABLE 272 INDIA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 207
TABLE 273 INDIA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 207
TABLE 274 INDIA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 208
TABLE 275 INDIA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 208
TABLE 276 INDIA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 208
TABLE 277 SOUTH KOREA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 209
TABLE 278 SOUTH KOREA: LIGASE ENZYMES MARKET, BY GRADE,
2023–2030 (USD MILLION) 209
TABLE 279 SOUTH KOREA: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 210
TABLE 280 SOUTH KOREA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 210
TABLE 281 SOUTH KOREA: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 210
TABLE 282 SOUTH KOREA: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 211
TABLE 283 AUSTRALIA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 284 AUSTRALIA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 212
TABLE 285 AUSTRALIA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 212
TABLE 286 AUSTRALIA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 212
TABLE 287 AUSTRALIA: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 213
TABLE 288 AUSTRALIA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 213
TABLE 289 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY TYPE,
2023–2030 (USD MILLION) 214
TABLE 290 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY GRADE,
2023–2030 (USD MILLION) 214
TABLE 291 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 214
TABLE 292 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY MOLECULAR
BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 215
TABLE 293 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 215
TABLE 294 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 215
TABLE 295 LATIN AMERICA: LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 216
TABLE 296 LATIN AMERICA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 216
TABLE 297 LATIN AMERICA: LIGASE ENZYMES MARKET, BY GRADE,
2023–2030 (USD MILLION) 217
TABLE 298 LATIN AMERICA: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 217
TABLE 299 LATIN AMERICA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 217
TABLE 300 LATIN AMERICA: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 218
TABLE 301 LATIN AMERICA: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 218
TABLE 302 LATIN AMERICA: MACROECONOMIC INDICATORS 219
TABLE 303 BRAZIL: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 219
TABLE 304 BRAZIL: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 220
TABLE 305 BRAZIL: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 220
TABLE 306 BRAZIL: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 220
TABLE 307 BRAZIL: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 221
TABLE 308 BRAZIL: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 221
TABLE 309 MEXICO: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 222
TABLE 310 MEXICO: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 222
TABLE 311 MEXICO: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 222
TABLE 312 MEXICO: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 223
TABLE 313 MEXICO: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 223
TABLE 314 MEXICO: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 223
TABLE 315 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY TYPE,
2023–2030 (USD MILLION) 224
TABLE 316 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY GRADE,
2023–2030 (USD MILLION) 224
TABLE 317 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 225
TABLE 318 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY MOLECULAR
BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 225
TABLE 319 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 225
TABLE 320 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 226
TABLE 321 MIDDLE EAST: LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 226
TABLE 322 MIDDLE EAST: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 227
TABLE 323 MIDDLE EAST: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 227
TABLE 324 MIDDLE EAST: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 227
TABLE 325 MIDDLE EAST: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 228
TABLE 326 MIDDLE EAST: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 228
TABLE 327 MIDDLE EAST: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 228
TABLE 328 MIDDLE EAST: MACROECONOMIC INDICATORS 229
TABLE 329 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 230
TABLE 330 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 230
TABLE 331 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY GRADE,
2023–2030 (USD MILLION) 230
TABLE 332 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 231
TABLE 333 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 231
TABLE 334 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 231
TABLE 335 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 232
TABLE 336 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 337 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 233
TABLE 338 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 233
TABLE 339 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY
WORKFLOW, 2023–2030 (USD MILLION) 233
TABLE 340 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 234
TABLE 341 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 234
TABLE 342 UAE: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 343 UAE: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 235
TABLE 344 UAE: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 235
TABLE 345 UAE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW,
2023–2030 (USD MILLION) 236
TABLE 346 UAE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 236
TABLE 347 UAE: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 236
TABLE 348 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY TYPE,
2023–2030 (USD MILLION) 237
TABLE 349 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY GRADE,
2023–2030 (USD MILLION) 237
TABLE 350 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 238
TABLE 351 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY MOLECULAR
BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 238
TABLE 352 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 238
TABLE 353 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 239
TABLE 354 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 355 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY GRADE,
2023–2030 (USD MILLION) 240
TABLE 356 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY SOURCE,
2023–2030 (USD MILLION) 240
TABLE 357 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 240
TABLE 358 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 241
TABLE 359 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY END USER,
2023–2030 (USD MILLION) 241
TABLE 360 AFRICA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 361 AFRICA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 242
TABLE 362 AFRICA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 242
TABLE 363 AFRICA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW,
2023–2030 (USD MILLION) 243
TABLE 364 AFRICA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243
TABLE 365 AFRICA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 243
TABLE 366 MACROECONOMIC OUTLOOK FOR AFRICA 244
TABLE 367 LIGASE ENZYMES MARKET: OVERVIEW OF STRATEGIES ADOPTED
BY KEY PLAYERS, 2021–2025 245
TABLE 368 LIGASE ENZYMES MARKET: DEGREE OF COMPETITION 248
TABLE 369 LIGASE ENZYMES MARKET: REGION FOOTPRINT 253
TABLE 370 LIGASE ENZYMES MARKET: TYPE FOOTPRINT 254
TABLE 371 LIGASE ENZYMES MARKET: SOURCE FOOTPRINT 254
TABLE 372 LIGASE ENZYMES MARKET: APPLICATION FOOTPRINT 255
TABLE 373 LIGASE ENZYMES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 258
TABLE 374 LIGASE ENZYMES MARKET: COMPETITIVE BENCHMARKING
OF KEY STARTUPS/SMES 259
TABLE 375 LIGASE ENZYMES MARKET: DEALS, JANUARY 2021–AUGUST 2025 261
TABLE 376 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 262
TABLE 377 NEW ENGLAND BIOLABS: PRODUCTS OFFERED 262
TABLE 378 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 264
TABLE 379 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 265
TABLE 380 QIAGEN N.V.: COMPANY OVERVIEW 267
TABLE 381 QIAGEN N.V.: PRODUCTS OFFERED 268
TABLE 382 PROMEGA CORPORATION: COMPANY OVERVIEW 270
TABLE 383 PROMEGA CORPORATION: PRODUCTS OFFERED 270
TABLE 384 TAKARA BIO INC.: COMPANY OVERVIEW 272
TABLE 385 TAKARA BIO INC.: PRODUCTS OFFERED 273
TABLE 386 DANAHER CORPORATION: COMPANY OVERVIEW 275
TABLE 387 DANAHER CORPORATION: PRODUCTS OFFERED 276
TABLE 388 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 278
TABLE 389 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 279
TABLE 390 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 280
TABLE 391 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 281
TABLE 392 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–AUGUST 2025 282
TABLE 393 MERCK KGAA: COMPANY OVERVIEW 283
TABLE 394 MERCK KGAA: PRODUCTS OFFERED 284
TABLE 395 ARCTICZYMES TECHNOLOGIES: COMPANY OVERVIEW 285
TABLE 396 ARCTICZYMES TECHNOLOGIES: PRODUCTS OFFERED 286
TABLE 397 BIOSYNTH: COMPANY OVERVIEW 287
TABLE 398 BIOSYNTH: PRODUCTS OFFERED 287
TABLE 399 HIMEDIA LABORATORIES: COMPANY OVERVIEW 288
TABLE 400 HIMEDIA LABORATORIES: PRODUCTS OFFERED 288
TABLE 401 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW 289
TABLE 402 LGC BIOSEARCH TECHNOLOGIES: PRODUCTS OFFERED 289
TABLE 403 INSPIRALIS LIMITED: COMPANY OVERVIEW 290
TABLE 404 INSPIRALIS LIMITED: PRODUCTS OFFERED 290
TABLE 405 BIONEER CORPORATION: COMPANY OVERVIEW 291
TABLE 406 BIONEER CORPORATION: PRODUCTS OFFERED 291
TABLE 407 GENO TECHNOLOGY INC.: COMPANY OVERVIEW 292
TABLE 408 MBR, INC.: COMPANY OVERVIEW 292
TABLE 409 ABCLONAL, INC.: COMPANY OVERVIEW 293
TABLE 410 NZYTECH: COMPANY OVERVIEW 294
TABLE 411 JENA BIOSCIENCE GMBH: COMPANY OVERVIEW 295
TABLE 412 CREATIVE ENZYMES: COMPANY OVERVIEW 295
TABLE 413 ENZYNOMICS CO., LTD.: COMPANY OVERVIEW 296
TABLE 414 BIOCAT GMBH: COMPANY OVERVIEW 297
TABLE 415 GENAXXON BIOSCIENCE: COMPANY OVERVIEW 298
TABLE 416 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW 299
TABLE 417 CANVAX: COMPANY OVERVIEW 300
TABLE 418 BIOTECHRABBIT: COMPANY OVERVIEW 301
TABLE 419 MCLAB: COMPANY OVERVIEW 302
LIST OF FIGURES
FIGURE 1 LIGASE ENZYMES MARKET SEGMENTATION & REGIONAL SCOPE 31
FIGURE 2 RESEARCH DESIGN METHODOLOGY 34
FIGURE 3 LIGASE ENZYMES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 36
FIGURE 4 GLOBAL LIGASE ENZYMES MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 37
FIGURE 5 GLOBAL MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS
(BOTTOM-UP APPROACH), 2024 38
FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.:
REVENUE ANALYSIS (2024) 38
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 40
FIGURE 8 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 40
FIGURE 9 LIGASE ENZYMES MARKET: CAGR PROJECTIONS, 2025−2030 42
FIGURE 10 LIGASE ENZYMES MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS 43
FIGURE 11 DATA TRIANGULATION METHODOLOGY 44
FIGURE 12 LIGASE ENZYMES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 47
FIGURE 13 LIGASE ENZYMES MARKET, BY SOURCE, 2025 VS. 2030 (USD MILLION) 48
FIGURE 14 LIGASE ENZYMES MARKET, BY GRADE, 2025 VS. 2030 (USD MILLION) 48
FIGURE 15 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW,
2025 VS. 2030 (USD MILLION) 49
FIGURE 16 LIGASE ENZYMES MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 49
FIGURE 17 LIGASE ENZYMES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 50
FIGURE 18 REGIONAL SNAPSHOT OF LIGASE ENZYMES MARKET 51
FIGURE 19 RISING GENOMCS & NGS ACTIVITIES TO PROPEL MARKET GROWTH 54
FIGURE 20 US AND DNA LIGASES COMMANDED LARGER MARKET SHARES IN 2024 55
FIGURE 21 DNA LIGASES ACCOUNTED FOR LARGEST SHARE OF LIGASE ENZYMES
MARKET IN 2024 55
FIGURE 22 ACADEMIC & RESEARCH INSTITUTES SEGMENT HELD LARGEST
MARKET SHARE IN 2024 56
FIGURE 23 CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 56
FIGURE 24 LIGASE ENZYMES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 60
FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
FIGURE 26 LIGASE ENZYMES MARKET: VALUE CHAIN ANALYSIS 68
FIGURE 27 LIGASE ENZYMES MARKET: ECOSYSTEM ANALYSIS 69
FIGURE 28 PATENT APPLICATIONS IN LIGASE ENZYMES MARKET,
JANUARY 2014–DECEMBER 2024 72
FIGURE 29 LIGASE ENZYMES MARKET: PORTER’S FIVE FORCES ANALYSIS 77
FIGURE 30 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES,
BY KEY PLAYER, 2022–2024 85
FIGURE 31 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024 86
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIGASE ENZYMES 87
FIGURE 33 KEY BUYING CRITERIA FOR END USERS 89
FIGURE 34 AI USE CASES 91
FIGURE 35 NORTH AMERICA: LIGASE ENZYMES MARKET SNAPSHOT 170
FIGURE 36 ASIA PACIFIC: LIGASE ENZYMES MARKET SNAPSHOT 198
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN LIGASE ENZYMES MARKET, 2020–2024 246
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LIGASE ENZYMES MARKET, 2024 247
FIGURE 39 LIGASE ENZYMES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 251
FIGURE 40 LIGASE ENZYMES MARKET: COMPANY FOOTPRINT 252
FIGURE 41 LIGASE ENZYMES MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2024 257
FIGURE 42 EV/EBITDA OF KEY VENDORS 260
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 260
FIGURE 44 LIGASE ENZYMES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 261
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 265
FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2024) 268
FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT (2024) 273
FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 276
FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 279
FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 281
FIGURE 51 MERCK KGAA: COMPANY SNAPSHOT (2024) 284
FIGURE 52 ARCTICZYMES TECHNOLOGIES: COMPANY SNAPSHOT (2024) 286
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 精密林業市場規模、シェア、動向、2030年までの世界予測 2025-11-05
- フィールドサービス管理市場規模、シェア、動向、2030年までの世界予測 2025-11-05
- 採血装置市場規模、シェア、動向、2030年までの世界予測 2025-11-04
- 車載半導体市場規模、シェア、動向、2030年までの世界予測 2025-11-04
- データセンターUPS市場規模、シェア、動向、2030年までの世界予測 2025-10-31